Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
Status:
Completed
Trial end date:
2018-01-05
Target enrollment:
Participant gender:
Summary
This study is to assess the longevity of immune response in adolescents for approximately 48
months after receipt of a primary series of bivalent rLP2086 vaccination, which is then
followed by a booster dose and an assessment of immune response for 12 or 26 months post
booster vaccination.